Slide 1: 2016 Progress Report
2016 Progress Report 10 March 2016 David Darling, CEO
Slide 2: 2016 Progress Report
2016 PROGRESS REPORT Chief Executive Officer, David Darling
Slide 3: Product Development
PRODUCT DEVELOPMENT Pacific Edge is the only cancer diagnostics company in the world to offer three proprietary molecular diagnostic products for the detection and management of bladder cancer and designed to meet different clinical needs. • Cxbladder Detect: Initially launched in New Zealand with U
Slide 4: USA Healthcare Market
USA HEALTHCARE MARKET EXPANDED US SALES • Achieved targeted sales force size with 18 sales executives covering 19 targeted major FORCE metropolitan regions • Pacific Edge has identified these regions as covering 60% of its potential market in the USA. LAUNCH OF NEW • Cxbladder Detect: In market sinc
Slide 5: Veterans Administration (VA)
VETERANS ADMINISTRATION (VA) THE VETERANS ADMINISTRATION IS ONE OF PACIFIC EDGE’S KEY CUSTOMERS • Federal funded healthcare for veterans and their families (funded separately to the CMS) • Approximately 20 million people under cover: ̵ 9.1 million to 10.2 million active enrollees ̵ A further 10 mill
Slide 6: Working with the Veterans Administration
WORKING WITH THE VETERANS ADMINISTRATION Completed Signed Federal Supply Schedule Agreement on 29 Feb 2016 Completed Identify leading VA centres with volume haematuria In progress Receipt of Award Package (usually within 4 weeks of signing). This will allow for the following activity to commence: Ne
Slide 7: Other Markets
OTHER MARKETS AUSTRALIA • February 2016: Announced new commercial partnership with Tolmar Australia Pty Limited, a specialised uro-oncology company which provides medicine and support to men with advanced prostate cancer • Tolmar will provide sales and marketing for Pacific Edge’s Cxbladder tests in
Slide 8: Canterbury DHB Commercial Agreement
CANTERBURY DHB COMMERCIAL AGREEMENT WORLD-FIRST AS CXBLADDER MOVES TO REPLACE CYTOLOGY IN CLINICAL GUIDELINES • Commercial Agreement announced on 9 March 2016 • Canterbury District Health Board will use Cxbladder technology in its new haematuria HealthPathway, replacing cytology • This is the first
Slide 9: Strategic Opportunities for Growth
STRATEGIC OPPORTUNITIES FOR GROWTH Targeting High Growth Over The Medium Term by Creating More Products and Building Sales in an Increasing Number of Markets • Development of suite of Cxbladder products More Products • IP over other cancer expressions with opportunity to develop specific diagnostic
Slide 10: Contact details
www.pacificedge.co.nz www.cxbladder.com www.pacificedgedx.com David Darling Chief Executive Officer Pacific Edge Limited Tel: +64 3 479 5802 Mobile: +64 21 797981 Email: dave.darling@pelnz.com
Slide 11: Disclaimer
DISCLAIMER Information The information in this presentation is an overview and does not contain all information necessary to make an investment decision. It is intended to constitute a summary of certain information relating to the performance of Pacific Edge Limited . The information in this presen